Skip to main content
. 2018 Apr 17;23(8):889–e98. doi: 10.1634/theoncologist.2018-0149

Figure 2.

image

Kaplan‐Meier curve of progression‐free survival in patients treated with rilotumumab in combination with bevacizumab. The inset table shows the progression‐free survival specifications for this regimen.

Abbreviation: CI, confidence interval.